The upside implied in the target price on this Canadian firm, developing regenerative medicine platform technologies, is 1,900%, noted an H.C. Wainwright & Co. report.
This pouch, loaded with pancreatic islet cells, is being evaluated in patients with insulin-dependent Type 1 diabetes, noted a Ventum Capital Markets report.